Programme

8 September 2023, Friday

Time Session
08:00
09:00
Registration
Foyer
09:00
10:30
Symposium 1A
Latest Evidence in Lipid Therapy
Chair:
Wan Azman Wan Ahmad Chair
  • 09:00
    09:25
    Familial Hypercholesterolemia: Recent and Novel Therapies
    Brian Tomlinson Speaker
  • 09:25
    09:50
    Updates on Therapy for Lowering Triglycerides and Lp(a)
    Edward Janus Speaker
  • 09:50
    10:15
    ORION-8: Long-term efficacy and safety of twice-yearly inclisiran in high cardiovascular risk patients
    Tan Ru San
  • 11:15
    10:30
    Panel Discussion
Summit 1
Symposium 1B
Vulnerable Plaque and Imaging (ISCP APSAVD Joint Symposium)
Chair:
Alan Fong Chair
  • 09:00
    09:25
    Chemokine Receptor Targeting PET Imaging of Atherosclerosis
    Osamu Baba Speaker
  • 09:25
    09:50
    Imaging in Vulnerable Plaque
    Tan Chen Ting Speaker
  • 09:50
    10:15
    The Vulnerable Plaque - What Therapies do we have in 2023?
    David Colquhoun Speaker
  • 10:15
    10:30
    Panel Discussion
Summit 2
10:30
10:45
Coffee Break, Booth & Poster Visit
Foyer
10:45
11:00
Opening Ceremony
Summit 1
11:00
11:45
Akira Yamamoto Plenary Lecture
Chair:
Hapizah Nawawi Chair
  • 11:00
    11:45
    Remnant Cholesterol
    Børge G Nordestgaard Speaker
Summit 1
11:45
12:45
Young Investigator Award Oral Presentation (Clinical)
  • 11:45
    11:55
    Greater Prevalence of Cardiovascular Risk Factors Among Rural Than Urban Malaysian Women
    Muhammad Nazirul Mubin Aziz Speaker
  • 11:55
    12:05
    Impact of Oxidative Stress on Aortic Vulnerable Plaques detected by Non-obstructive General Angioscopy
    Keisuke Kojima Speaker
  • 12:05
    12:15
    Real-World Effectiveness of siRNA Therapy (Inclisiran) in Malaysia – A Single Centre Experience
    Yew Kuan Leong Speaker
  • 12:15
    12:25
    Identification of ABCG5 and ABCG8 pathogenic variants among clinically diagnosed familial hypercholesterolaemia subjects in Malaysia: a community-based study
    Muhammad Nazirul Mubin Aziz Speaker
  • 12:25
    12:35
    Frequency Of Pathogenic Variants And Evaluation Of Coronary Risk Factors Among Premature Coronary Artery Disease Patients With Familial Hypercholesterolaemia
    Rahayu Binti Zulkapli Speaker
Summit 1
Young Investigator Award Oral Presentation (Basic Science)
  • 11:45
    11:55
    The association between Lp(a) and PCSK9 concentrations in patients with premature coronary artery disease with familial hypercholesterolaemia compared to controls
    Rahayu Binti Zulkapli Speaker
  • 11:55
    12:05
    Investigating the role of PERK in the regulation of macrophage lipid metabolism and foam cell formation: focus on atherogenesis
    Mariam Bagheri Ekta Speaker
  • 12:05
    12:15
    The role of NF-kB pathway in foam cell formation
    Arthur Lee Speaker
  • 12:15
    12:25
    E498A And R499G Variants Of PCSK9 Enhanced PCSK9-LDLR Binding - Insight From Molecular Dynamics Simulations
    Nur Alya Amirah Azhar Speaker
  • 12:25
    12:35
    Bisphenol A (BPA) and its analogue bisphenol S (BPS) increase risk of metabolic syndrome (MetS) in Malaysian adults
    Sarah Zulkifli Speaker
  • 12:35
    12:45
    Investigating Neuraminidase Gene Expression Patterns in Atherosclerotic Lesions: Insights into LDL Modification
    Mariam Bagheri Ekta Speaker
Summit 2
12:45
14:30
Lunch Symposium Sponsored by Amgen
  • 12:45
    12:50
    Opening Remark
    Azhari Rosman
  • 12:50
    13:15
    Earlier, Rapid and Consistent Lipid Lowering Strategy for ACS
    Chee Kok Han
  • 13:15
    13:40
    Coronary Imaging and Implications for Lipid Lowering
    David Colquhoun
  • 13:40
    13:55
    Which Patient for Advanced Lipid Lowering Therapy? - A Case Study
    Goay Swee En
  • 13:55
    14:10
    Improving CV Outcomes with PCSK9 Inhibition - A Case Study
    Ong Mei Lin
  • 14:10
    14:30
    Panel Discussion and Closing
Summit 1
14:30
16:00
Symposium 2A
Dyslipidaemic Patients (APSAVD EAS MSA Joint Symposium)
Chair:
Shizuya Yamashita Chair
  • 14:30
    14:55
    EAS-FHSC Registry - Lessons Learnt
    Kausik Ray Speaker
  • 14:55
    15:20
    Assessing cardiovascular risk in Asian patients
    Brian Tomlinson Speaker
  • 15:20
    15:45
    The Malaysian FH Registry - Sharing Experience
    Hapizah Nawawi Speaker
  • 15:45
    16:00
    Panel Discussion
Summit 1
Symposium 2B
Updates on Lipid Guideline from Around the World
Chair:
Rody Sy Chair
  • 14:30
    14:55
    ESC and ACC
    Syadi Zuhdi Speaker
  • 14:55
    15:20
    Malaysia CPG on Lipid 2023
    Jeyamalar Rajadurai Speaker
  • 15:20
    15:45
    How to Use Lipid Guidelines in Daily Practice
    Chua Seng Keong Speaker
  • 15:45
    16:00
    Panel Discussion
Summit 2
16:00
17:30
Symposium 3A
Addressing ASCVD Risk in Patients with Chronic Kidney Disease
Chair:
Mohd Al-Baqlish Mohd Firdaus Chair
  • 16:00
    16:25
    Burden of ASCVD in CKD patients
    Sunita Bavanandan Speaker
  • 16:25
    16:50
    Characteristic Features of Dyslipidemia and Its Treatment in CKD Patients
    Shizuya Yamashita Speaker
  • 16:50
    17:15
    Treatment Options in CKD Patients
    Muhammad Iqbal Abdul Hafidz Speaker
  • 17:15
    17:30
    Panel Discussion
Summit 1
Symposium 3B
ASCVD Disease Burden from Different Regions (APSAVD EAS MSA Joint Symposium)
Chair:
  • 16:00
    16:25
    Australia
    Edward Janus Speaker
  • 16:25
    16:50
    Denmark
    Børge G Nordestgaard Speaker
  • 16:50
    17:15
    Malaysia
    Alan Fong Speaker
  • 17:15
    17:30
    Panel Discussion
Summit 2
17:45
18:45
APSAVD AGM (APSAVD Members Only)
Summit 1